BioCryst Pharmaceuticals ... (BCRX)
Company Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.
The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.
BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Country | United States |
IPO Date | Mar 4, 1994 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 580 |
CEO | Jon P. Stonehouse |
Contact Details
Address: 4505 Emperor Boulevard Durham, North Carolina United States | |
Website | https://www.biocryst.com |
Stock Details
Ticker Symbol | BCRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000882796 |
CUSIP Number | 09058V103 |
ISIN Number | US09058V1035 |
Employer ID | 62-1413174 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Jon P. Stonehouse | Chief Executive Officer, President & Executive Director and Interim Chief Financial Officer, Principal Accounting Officer |
Alane P. Barnes | Senior Vice President, Chief Legal Officer & Corporate Secretary |
Stephanie Angelini | Chief People Officer |
Charles K. Gayer | Senior Vice President & Chief Commercial Officer |
Dr. Helen M. Thackray FAAP, M.D. | Chief Research & Development Officer |
Dr. William P. Sheridan MBBS | Chief Development Officer |
Dr. Yarlagadda S. Babu Ph.D. | Chief Discovery Officer |
Jinky Ang Rosselli | Chief Data & Insights Officer |
John D. Bluth | Chief Communications Officer |
Philip George | Chief Strategy Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 24, 2025 | ARS | Filing |
Apr 24, 2025 | DEFA14A | Filing |
Apr 24, 2025 | DEF 14A | Filing |
Apr 17, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Apr 10, 2025 | 8-K | Current Report |
Apr 02, 2025 | 4 | Filing |
Mar 11, 2025 | 8-K | Current Report |
Mar 04, 2025 | 4 | Filing |
Mar 04, 2025 | 8-K | Current Report |
Feb 25, 2025 | 10-K | Annual Report |